Novavax vaccine trials run in South Africa and the UK indicate that its efficacy in the UK was 89% at least 7 days after individuals had received two doses of vaccine. In South Africa, the vaccine efficacy was 60% in people living without HIV.
The trial is being viewed as highly significant because it is the first vaccine to be tested on a particular COVID-19 variant first identified in South Africa.
In today’s episode of Pasha Shabir Madhi, professor of vaccinology and director of the vaccines and infectious diseases analytics research unit at the University of the Witwatersrand, explains the results as well as the context of this and other vaccine trials.